Print
Email
Print Edition StoriesWednesday, June 4, 2008
Insulet pump picked for first non-insulin use
By Mass High Tech Staff
Insulet Corp., a maker of wearable insulin pumps, reports it has entered into its first agreement to develop its technology outside of the field of diabetes care.
The Bedford-based medical devices company said that Swiss drug company Ferring Pharmaceuticals plans to adapt Insulet’s OmniPod system — which is an insulin-injecting device worn over the skin — to deliver a Ferring treatment for women’s health.
Insulet (Nasdaq: PODD) didn’t disclose financing details of the deal or which Ferring drug the Swiss firm plans to inject with OmniPods. Ferring, which has a U.S. subsidiary based in New Jersey, markets several female fertility treatments taken by injection. A call to Insulet was not immediately returned before press time this morning.
Insulet, which employs 247 workers, reported a 2007 net loss of $53.5 million on revenue of $13.4 million. The company completed an $115.5 million initial public offering in May 2007.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
